{"id":477467,"date":"2020-04-02T12:42:01","date_gmt":"2020-04-02T12:42:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=477467"},"modified":"2020-04-02T12:42:01","modified_gmt":"2020-04-02T12:42:01","slug":"retinitis-pigmentosa-pipeline-insights-2020","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/retinitis-pigmentosa-pipeline-insights-2020_477467.html","title":{"rendered":"Retinitis Pigmentosa Pipeline Insights, 2020"},"content":{"rendered":"
\"Retinitis<\/a><\/p>\n
\n
DelveInsight <\/div>\n<\/div>\n<\/div>\n
“Retinitis Pigmentosa Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Retinitis Pigmentosa (RP) market. A detailed picture of the Retinitis Pigmentosa pipeline landscape is provided, which includes the disease overview and Retinitis Pigmentosa treatment guidelines. <\/div>\n

DelveInsight launched a new report on Retinitis Pigmentosa Pipeline Insights, 2020<\/a><\/p>\n

 <\/strong><\/p>\n

Some of the key facts of the report:-<\/strong><\/p>\n

Horama is developing a gene therapy candidate HORA-RPE65 in Phase III for the treatment of Autosomal Recessive RP (Non syndromic) RPE65 RP. It is an AAV 2\/4 encapsidating the human RPE65 gene under the control of the human native RPE65 promoter. The company’s investigational candidate HORA-RPE65 provides the cell with a non-mutated copy of the human RPE65 gene, which can express functional RPE65 protein to halt or at least significantly delay retinal degeneration in patients with inherited retinal dystrophies caused by RPE65 gene mutations.<\/p>\n

Nightstar Therapeutics (acquired by Biogen) is developing a sub-retinal AAV-based Adeno-Associated Viral Vector Encoding RP GTPase Regulator gene therapy (AAV8-RPGR) in Phase II\/III for Non syndromic X-linked Retinitis Pigmentosa (XLRP). The company’s NSR-RPGR gene therapy consists of a standard AAV8 vector, including the codon-optimized human RPGR DNA. The drug candidate has already demonstrated positive outcomes in the initial Phase of the Phase II\/III XIRIUS trial.<\/p>\n

jCyte is evaluating jCell human retinal progenitor cells in a Phase II trial in in Adult patients with RP. The company’s investigational therapy uses adult retinal progenitor cells to rescue rods and cones from RP progression and possibly generate new retinal cells. The treatment requires a single intravitreal injection, which can be performed in with topical anesthetic. jCyte have already completed a phase I\/IIa study to determine the therapy’s safety. Furthermore, the drug received US FDA Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) designation.<\/p>\n

Neurotech is currently evaluating Renexus (NT-501) in a Phase II in Participants with Syndromic RP Using Rates of Change in Cone Spacing and Density. Renexus (NT-501) Consists of encapsulated human cells genetically modified to secrete therapeutic doses of ciliary neurotrophic factor in to the back of eye for the treatment of RP. The drug candidate was granted orphan drug and fast-track designation by the US FDA for RP.<\/p>\n

ReNeuron is currently leading a Phase IIa trial for the assessment of proprietary cGMP-produced, Subretinal, allogeneic, cryopreserved human retinal progenitor cells (hrpc) cell. The company received Orphan Drug in EU and US & Fast Track Designation for in US, for hrpc, for the treatment of RP.<\/p>\n

 <\/strong><\/p>\n

Request for sample pages:- https:\/\/www.delveinsight.com\/sample-request\/retinitis-pigmentosa-pipeline-insight<\/a><\/p>\n

 <\/p>\n

Scope of the Report<\/strong><\/p>\n